Evaluation of the HbA1c Reduction Cut Point for a Nonglycemic Effect on Cardiovascular Benefit of Hypoglycemic Agents in Patients with Type 2 Diabetes Based on Endpoint Events
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Endocrinology"
DOI: 10.1155/2018/8457538
Abstract: Background Atherosclerotic cardiovascular disease (ASCVD) is a major cause of death among patients with diabetes but can be improved by certain hypoglycemic agents. However, adjudicating criteria on whether improvements are a glycemic or nonglycemic effect… read more here.
Keywords: reduction; effect; nonglycemic effect; hypoglycemic agents ... See more keywords